公开(公告)号：US20240336563A1

公开(公告)日：2024-10-10

申请号：US18287634

申请日：2022-04-26

Applicant: The Regents of the University of California

Inventor： Kevan M. Shokat ,  Qi Hu ,  Shizhong Dai

IPC: C07C323/44 ,  A61K31/165 ,  A61K31/17 ,  A61K31/381 ,  A61K31/41 ,  A61K31/42 ,  A61K31/433 ,  A61K31/505 ,  A61K31/53 ,  A61K47/64 ,  A61P35/00 ,  C07D213/75 ,  C07D239/34 ,  C07D257/06 ,  C07D261/14 ,  C07D285/135 ,  C07D333/70

CPC classification number: C07C323/44 ,  A61K31/165 ,  A61K31/17 ,  A61K31/381 ,  A61K31/41 ,  A61K31/42 ,  A61K31/433 ,  A61K31/505 ,  A61K31/53 ,  A61K47/64 ,  A61P35/00 ,  C07D213/75 ,  C07D239/34 ,  C07D257/06 ,  C07D261/14 ,  C07D285/135 ,  C07D333/70

Abstract: Disclosed herein, inter alia, are G-alpha-s Inhibitors and uses thereof.

公开(公告)号：US20240327340A1

公开(公告)日：2024-10-03

申请号：US18692114

申请日：2022-09-20

Applicant: Hangzhou PhecdaMed Co., Ltd.

Inventor： Hongguang XIA ,  Mengyang FAN ,  Xufeng CEN ,  Xiaoyan XU ,  Ronghai WU ,  Dong LIU ,  Zhen TIAN

IPC: C07C317/34 ,  A61K31/18 ,  A61K31/40 ,  A61K31/41 ,  C07D207/04 ,  C07D249/04 ,  C07D257/04

CPC classification number: C07C317/34 ,  A61K31/18 ,  A61K31/40 ,  A61K31/41 ,  C07D207/04 ,  C07D249/04 ,  C07D257/04

Abstract: The present application discloses small molecule compounds having a naphthylamine structure and an application thereof. In the present application, the structure of a compound having a structure as shown in general formula (I) is as shown in the drawing. The compound and the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof that are provided by the present application or the pharmaceutical composition provided by the present application can selectively induce autophagy in damaged mitochondria without affecting or only weakly affecting normal mitochondria, and further have superior metabolic stability and pharmacokinetic properties, lower toxicity, and better druggability.

公开(公告)号：US20240277666A1

公开(公告)日：2024-08-22

申请号：US18569263

申请日：2022-06-14

Applicant: Scandion Oncology A/S

Inventor： Peter Michael Vestlev ,  Nicklas Lindland Roest

IPC: A61K31/41 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61P35/00 ,  G01N33/72

CPC classification number: A61K31/41 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61P35/00 ,  G01N33/728 ,  G01N2800/52

Abstract: The present invention relates to treatment of subgroups of cancer patients, methods for identifying treatment and dosage regimens, as well as methods for identifying these subgroups of cancer patients.

公开(公告)号：US20240245693A1

公开(公告)日：2024-07-25

申请号：US18289823

申请日：2022-05-20

Applicant: The Regents of the University of California

Inventor： Ichiro NISHIMURA ,  Akishige HOKUGO ,  Takeru KONDO ,  Yoichiro SHIBUYA

IPC: A61K31/5377 ,  A61K31/40 ,  A61K31/41 ,  A61K31/438 ,  A61K31/4745 ,  A61K31/48 ,  A61K31/496 ,  A61K45/06 ,  A61P17/02

CPC classification number: A61K31/5377 ,  A61K31/40 ,  A61K31/41 ,  A61K31/438 ,  A61K31/4745 ,  A61K31/48 ,  A61K31/496 ,  A61K45/06 ,  A61P17/02

Abstract: Using a reversed-phase high-performance liquid chromatographic (HPLC) technique, a mixture of antimycins A was separated into eight hitherto unreported subcomponents, Ala, Alb, A2a, A2b, A3a, A3b, Ma, and A4b. Although a base-line resolution of the known four major antimycins Al, A2, A3, and A4 was readily achieved with mobile phases containing acetate buffers, the separation of the new antibiotic subcomponents was highly sensitive to variation in mobile phase conditions. The type and composition of organic modifiers, the nature of buffer salts, and the concentration of added electrolytes had profound effects on capacity factors, separation factors, and peak resolution values. Of the numerous chromatographic systems examined, a mobile phase consisting of methanol-water (70:30) and 0.005 M tetrabutylammonium phosphate at pH 3.0 yielded the most satisfactory results for the separation of the subcomponents. Reversed-phase gradient HPLC separation of the dansylated or methylated antibiotic compounds produced superior chromatographic characteristics and the presence of added electrolytes was not a critical factor for achieving separation. Differences in the chromatographic outcome between homologous and structural isomers were interpretated based on a differential solvophobic interaction rationale. Preparative reversed-phase HPLC under optimal conditions enabled isolation of pure samples of the methylated antimycin subcomponents for use in structural studies.

公开(公告)号：US20240228446A1

公开(公告)日：2024-07-11

申请号：US18552784

申请日：2022-03-30

Applicant: SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD ,  JIANGXI JEMINCARE GROUP CO., LTD

Inventor： Gang DENG ,  Yucai YAO ,  Xiaobin LIU ,  Zhongyao LI ,  Ming DAI ,  Rui HUAN ,  Rui TANG ,  Daochen HUANG ,  Qiong ZHANG ,  Yu WANG ,  Yan YE ,  Jianbiao PENG

IPC: C07D257/04 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61P31/10 ,  C07D231/12 ,  C07D249/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/08 ,  C07D405/14 ,  C07D413/08 ,  C07D417/12 ,  C07F9/6524

CPC classification number: C07D257/04 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61P31/10 ,  C07D231/12 ,  C07D249/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/08 ,  C07D405/14 ,  C07D413/08 ,  C07D417/12 ,  C07F9/6524

Abstract: A compound represented by formula (I) and a pharmaceutically acceptable salt thereof, as well as an antifungal application of the compound.

公开(公告)号：US20240173302A1

公开(公告)日：2024-05-30

申请号：US18282105

申请日：2022-03-18

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Robert Pearson Shepherd ,  Nina Webster

IPC: A61K31/422 ,  A61K31/194 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K38/12

CPC classification number: A61K31/422 ,  A61K31/194 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K38/12

Abstract: A pharmaceutical composition comprising at least one endothelin A receptor inhibitor or a pharmaceutically acceptable salt thereof and at least one chemokine receptor 2 (CCR2) inhibitor or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11957755B2

公开(公告)日：2024-04-16

申请号：US17329891

申请日：2021-05-25

Applicant: Boston Scientific Medical Device Limited

Inventor： Stephane Hohn ,  Andrew Lennard Lewis ,  Sean Leo Willis ,  Matthew R. Dreher ,  Koorosh Ashrafi ,  Yiqing Tang

IPC: A61K9/00 ,  A61K31/404 ,  A61K31/41 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/517 ,  A61K31/555 ,  A61K31/704 ,  A61K47/34 ,  A61K49/04

CPC classification number: A61K47/34 ,  A61K9/0024 ,  A61K31/404 ,  A61K31/41 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/517 ,  A61K31/555 ,  A61K31/704 ,  A61K49/0442 ,  A61K49/0457 ,  A61K49/048

Abstract: Radiopaque hydrogels, in particular radiopaque hydrogel microspheres, comprising a polymer having 1,2-dil or 1,3-diol groups acetalized with radiopaque species.

公开(公告)号：US11934784B2

公开(公告)日：2024-03-19

申请号：US17838461

申请日：2022-06-13

Applicant: Verint Americas Inc.

Inventor： Ian Roy Beaver

IPC: G06F40/289 ,  A61K31/198 ,  A61K31/215 ,  A61K31/216 ,  A61K31/401 ,  A61K31/41 ,  A61K38/18 ,  G06N20/00

CPC classification number: G06F40/289 ,  A61K31/198 ,  A61K31/215 ,  A61K31/216 ,  A61K31/401 ,  A61K31/41 ,  A61K38/1841 ,  G06N20/00

Abstract: A system and method for updating computerized language models is provided that automatically adds or deletes terms from the language model to capture trending events or products, while maximizing computer efficiencies by deleting terms that are no longer trending and use of knowledge bases, machine learning model training and evaluation corpora, analysis tools and databases.

公开(公告)号：US11878003B2

公开(公告)日：2024-01-23

申请号：US17448755

申请日：2021-09-24

Applicant: Gwangju Institute of Science and Technology

Inventor： Darren Reece Williams ,  Da-Woon Jung ,  Ji-Hyung Lee ,  Hyun-Jun Kim ,  Seon-Wook Kim

IPC: A61K31/41 ,  A61P21/06 ,  A23L33/10

CPC classification number: A61K31/41 ,  A23L33/10 ,  A61P21/06

Abstract: This application relates to a composition for preventing, treating, and improving skeletal muscle atrophy, the composition including an organoselenium compound. The composition recovered the thickness of muscle fiber reduced by dexamethasone treatment. In addition, the treatment of mice in a muscle loss model showed that the composition had an effect of reducing damaged muscle and of restoring muscle mass. Therefore, it is expected that the composition can be effectively used for the treatment, prevention, or improvement of muscle atrophy.

公开(公告)号：US20240009191A1

公开(公告)日：2024-01-11

申请号：US17675320

申请日：2020-09-18

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Robert Pearson Shepherd ,  Kevin Donald George Pfleger

IPC: A61K31/506 ,  A61K31/4192 ,  A61K31/17 ,  A61K31/341 ,  A61K31/4462 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/4178 ,  A61K31/41 ,  A61P11/00

CPC classification number: A61K31/506 ,  A61K31/4192 ,  A61K31/17 ,  A61K31/341 ,  A61K31/4462 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/4178 ,  A61K31/41 ,  A61P11/00

Abstract: A pharmaceutical formulation comprising at least one angiotensin type 1 receptor (AT1R) blocker and at least one CXC chemokine receptor 2 (CXCR2) pathway inhibitor.